Bristol-Myers Squibb Co. (BMY)

44.34
0.15 0.34
NYSE : Health Technology
Prev Close 44.19
Open 44.15
Day Low/High 44.08 / 44.48
52 Wk Low/High 43.81 / 63.69
Volume 2.13M
Avg Volume 13.64M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 72.41B
EPS 3.00
P/E Ratio 14.10
Div & Yield 1.64 (3.64%)

Latest News

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Bristol-Myers Squibb Completes Divestment Of UPSA

Bristol-Myers Squibb Completes Divestment Of UPSA

Bristol-Myers Squibb Company (NYSE:BMY) announced today that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA, to Taisho Pharmaceutical Co.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

Bristol-Myers Squibb Company Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corporation Notes

Bristol-Myers Squibb Company Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corporation Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene Corporation (NASDAQ:CELG) ("Celgene") for...

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks

Stocks end little changed Monday as investors look to the upcoming G-20 summit for a breakthrough in talks between the world's two largest economies.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal

Bristol-Myers Squibb slumped to the bottom of the S&P 500 Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.

Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears

Dow Futures Rise, Global Stocks Edge Higher, as US-China Trade Detente Nears

U.S. stocks look set to test all time highs again Monday, following a third consecutive weekly gain for all three benchmarks on Wall Street, as investors continue to bet that central bank support will boost global equities and this weekend's G20 Summit in Osaka will trigger a breakthrough in U.S.-China trade talks.

Bristol-Myers Squibb Announces Results From CheckMate -459 Study Evaluating Opdivo (nivolumab) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Bristol-Myers Squibb Announces Results From CheckMate -459 Study Evaluating Opdivo (nivolumab) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo (nivolumab) versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma (HCC).

Bristol-Myers Squibb Provides Update On Pending Merger With Celgene

Bristol-Myers Squibb Provides Update On Pending Merger With Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG).

Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.

Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

Bristol-Myers Squibb Presents Updated Efficacy Data From Phase 2 Trial Of Empliciti (elotuzumab) Plus Pomalidomide And Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma (RRMM)

Bristol-Myers Squibb Presents Updated Efficacy Data From Phase 2 Trial Of Empliciti (elotuzumab) Plus Pomalidomide And Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma (RRMM)

Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of updated data from ELOQUENT-3, the international randomized Phase 2 study evaluating Empliciti (elotuzumab) plus pomalidomide and dexamethasone (EPd) versus pomalidomide and...

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.

New Mechanistic Study Explores The Relationship Between A Key Genetic Marker And Clinical Efficacy Of ORENCIA® (abatacept) Or Adalimumab In Moderate-to-Severe Early Rheumatoid Arthritis Patients

New Mechanistic Study Explores The Relationship Between A Key Genetic Marker And Clinical Efficacy Of ORENCIA® (abatacept) Or Adalimumab In Moderate-to-Severe Early Rheumatoid Arthritis Patients

Bristol-Myers Squibb Company (NYSE:BMY) today announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA ® (abatacept) and another treatment, adalimumab, interfere with disease...

The S&P's Death-Zone?

Just like the world's tallest mountains, the S&P 500 can seem to run out of oxygen at the top -- and over 29,000 felt Tuesday like a trip too high -- but there's still room to breathe.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Bristol-Myers Squibb To Announce Results For Second Quarter 2019 On July 25, 2019

Bristol-Myers Squibb To Announce Results For Second Quarter 2019 On July 25, 2019

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2019 on Thursday, July 25, 2019.

Bristol-Myers Squibb Announces Post-Closing Leadership Team

Bristol-Myers Squibb Announces Post-Closing Leadership Team

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company's pending merger with Celgene Corporation (NASDAQ:CELG).

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.

TheStreet Quant Rating: C+ (Hold)